



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

Bar-Or

Serial No.: 10/723,247

Filed: November 25, 2003

Atty. File No.: 4172-82

For: "TREATMENT OF DISEASES AND
CONDITIONS MEDIATED BY
INCREASED PHOSPHORYLATION"

) Group Art Unit:

) Examiner:

INFORMATION DISCLOSURE
STATEMENT

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA
VA 22313-1450 ON JUNE 24, 2004.

SHERIDAN ROSS P.C.

BY: 

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Dear Sir:

Pursuant to Applicant's duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicant hereby provides a copy of each of the documents identified on the enclosed PTO Form 1449. Applicant does not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicant that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: 

Gary J. Conner
Registration No. 32,020
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: June 24, 2004



FORM 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	A1.	6,355,297	3/12/2002	Sawatzki et al.	426	657	
	A2.	6,355,297	3/12/2002	Sawatzki et al.	426	657	
	A3.	6,329,155	12/11/2001	Nitsch et al.	435	7.21	
	A4.	6,270,827	8/7/2001	Gaull et al.	426	580	
	A5.	6,268,194	7/31/2001	Karin et al.	435	194	
	A6.	6,242,253	6/5/2001	Karin et al.	435	325	
	A7.	6,232,094	5/15/2001	Hansson et al.	435	069.1	
	A8.	6,147,080	11/14/2000	Bemis et al.	514	258	
	A9.	6,093,742	7/25/2000	Salituro et al.	514	596	
	A10.	5,952,295	9/14/1999	Arnaud-Battandier et al.	514	2	
	A11.	5,945,418	8/31/1999	Bemis et al.	514	248	
	A12.	5,942,274	8/24/1999	Slattery	426	580	
	A13.	5,932,580	8/3/1999	Levitzki et al.	514	249	
	A14.	5,902,786	5/11/1999	Bregman	514	2	
	A15.	5,795,611	8/18/1998	Slattery	426	580	
	A16.	5,739,407	4/14/1998	Bergstrom et al.	800	007	
	A17.	5,583,221	12/10/1996	Hu et al.	540	520	
	A18.	5,432,198	7/11/1995	Jagdmann, Jr.	514	544	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	A19.	5,385,915	1/31/1995	Buxbaum et al.	514	313	
	A20.	5,352,476	10/4/1994	Brule et al.	426	657	
	A21.	5,344,841	9/6/1994	Jiang et al.	514	459	
	A22.	5,334,408	8/2/1994	Brule et al.	426	57	
	A23.	5,292,737	3/8/1994	Defauw	514	247	
	A24.	5,279,814	1/18/1994	Wuelknitz et al.	424	52	
	A25.	5,270,310	12/14/1993	Bell et al.	514	238.2	
	A26.	5,216,014	6/1/1993	Jiang et al.	514	455	
	A27.	5,204,370	4/20/1993	Jiang et al.	514	475	
	A28.	5,189,046	2/23/1993	Burch et al.	514	330	
	A29.	5,141,957	8/25/1992	Jiang et al.	514	510	
	A30.	5,130,123	7/14/1992	Reynolds et al.	424	49	
	A31.	5,068,118	11/26/1991	Strandholm	426	582	
	A32.	4,777,243	10/11/1988	Jolles et al.	530	300	
	A33.	4,462,990	7/31/1984	Jolles et al.	424	177	
	A34.	4,419,369	12/6/1983	Nichols et al.	426	002	
	A35.	4,358,465	11/9/1982	Brule et al.	435	068.1	
	A36.	4,284,623	8/18/1981	Beck	424	85	
	A37.	3,966,915	6/29/1976	Caprino	424	177	
	A38.	3,901,979	8/26/1975	Nagasawa et al.	426	613	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	A39.	3,558,770	1/26/1971	Gordon et al.	424	80	
	A40.	2001/0025044 A1	9/27/2001	Salituro et al.	514	259	12/11/2000

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY				
	A41.	WO 02/04949	1/17/02	PCT				
	A42.	JP 2001/0107122 A2	1/23/2001	Japan				
	A43.	WO 01/22837 A1	4/5/2001	PCT				
	A44.	JP 10203996 A2	8/4/1998	Japan				
	A45.	EP 0862450 A2	9/9/1998	EPO				
	A46.	EP 0760674 A1	2/12/1997	EPO				
	A47.	WO 96/06530	3/17/1996	PCT				
	A48.	EP 0 699 444 A2	306/1996	EPO				
	A49.	JP 5025032 A2	2/2/1993	Japan				
	A50.	WO 92/18526	10/29/1992	PCT				
	A51.	JP 3056500 A2	3/12/1991	Japan				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	A52.	Aitken, Protein consensus sequence motifs, <i>Mol Biotechnol</i> 1999, 12(3):241-53, Abstract only , from PubMed - PMID:10631681
--	------	---

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

A53.	Casein Kinase II Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
A54.	Casein Kinase I Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/19/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
A55.	Casein Kinase I Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
A56.	cdc2 Protein Kinase Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
A57.	cGMP-Dependent Protein Kinase (PKG) Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
A58.	Cohen et al., The development and therapeutic potential of protein kinase inhibitors, <i>Current Opinion in Chemical Biology</i> 1999, 3:459-465
A59.	DNA-Dependent Protein Kinase Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
A60.	Hata et al., Identification of a phosphopeptide in bovine α_{s1} -casein digest as factor influencing proliferation and immunoglobulin production in lymphocyte cultures, <i>Journal of Sairy Research</i> 1998 65:569-578
A61.	Jiang et al., Preparation of novel functional oligophosphopeptides from hen egg yolk phosvitin, <i>J. Agric Food Chem</i> 2000, 48(4):990-994, Abstract only , from PubMed - PMID:10775339
A62.	Jourd'heuil et al., Oxidant-regulation of gene expression in the chronically inflamed intestine, <i>Keio J. Med.</i> 1997, 46(1):10-15, Abstract only , from PubMed - PMID:9095577
A63.	Kemptide (PKA) Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
A64.	Kreegipuu et al., PhosphoBase, a database of phosphorylation sites: release 2.0, <i>Nucleic Acids Research</i> 1999, 27(1):237-239
A65.	Lee et al., Inhibition of p38 MAP kinase as a therapeutic strategy, <i>Immunopharmacology</i> 2000, 47(2):185-201, Abstract only , from PubMed - PMID:10878289
A66.	Lee et al., Antioxidant Activity of Phosvitin in Phosphatidylcholine Liposomes and Meat Model Systems, <i>J. of Food Science</i> 2002, 67(1), Abstract only

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

A67.	Miller et al., Dephosphorylation of chicken riboflavin-binding protein and phosvitin decreases their uptake by oocytes, <i>Journal of Biological Chemistry</i> 1982, 257 (12):6818-6824
A68.	Neurogranin ₍₂₈₋₄₃₎ (PKC) Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...>
A69.	PhosphoBase v2.0, A database of phosphorylation sites, provided by Center for Biological Sequence Analysis (CBS) [online] [retrieved on 11/26/2002]. Retrieved from the Internet:<URL:http://www.cbs.dtu.dk/databases/PhosphoBase/>
A70.	Phosphoprotein Database (PPDB), Introduction to the phosphoprotein database* [online] [retrieved on 11/26/2002]. Retrieved from the Internet:<URL:http://www-lmmb.ncifcrf.gov/phosphoDB/>
A71.	Shanley, Phosphates: counterregulatory role in inflammatory cell signaling, <i>Crit Care Med</i> 2002, 30 (1)(Suppl.):S80-S88
A72.	Songyang et al., Use of an oriented peptide library to determine the optimal substrates of protein kinases, <i>Curr Biol.</i> 1994, 4 (11):973-982, Abstract only , from PubMed - PMID:7874496
A73.	Worthington Casein, Alpha, Manual Page, Worthington-biochem.com [online] [retrieved on 11/20/2003]. Retrieved from the Internet:<URL:http://www.worthington-biochem.com/CASA/default.html>
A74.	Wu et al., Identifying substrate motifs of protein kinases by a random library approach, <i>Biochemistry</i> 1994, 33 (49):14825-33, Abstract only , from PubMed - PMID:7993909

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	